Volitionrx LTD 8-K filings

VolitionRx Limited has appointed Dr. Ethel Rubin as an independent director, effective September 30, 2024, also naming her to the Audit and Compensation Committees.

VolitionRx has restructured the employment and consulting agreements for Dr. Gaetan Michel, ensuring his continued service as CEO of Belgian Volition and expanding his role across the company's subsidiaries.

VolitionRx Limited is making available a document to third parties, including its licensing advisor, PharmaVentures Limited, outlining components of its oncology portfolio available for out-licensing.

VolitionRx announced an 83% increase in second-quarter revenue and significant progress in commercializing its Nu.Q Vet Cancer Test and preparing for human licensing deals.

VolitionRx Limited has announced a registered direct offering, raising $7 million upfront and potentially an additional $14.5 million through milestone-linked warrants.

VolitionRx Limited's stockholders approved a new stock incentive plan and an increase in authorized shares at their annual meeting on July 2, 2024.

VolitionRx has expanded the availability of its Nu.Q Vet Cancer Test to 15 countries and is preparing for licensing deals in the human space.

VolitionRx reported a 15% increase in revenue year-over-year for Q1 2024, alongside a strategic shift towards commercialization and cost reduction.

VolitionRx Limited disclosed the retirement of two board members, a reduction in board size, and an amendment to its bylaws regarding quorum requirements for stockholder meetings.

VolitionRx reported a 153% increase in revenue for 2023, driven by sales of its Nu.Q Vet Cancer Test, and highlighted progress in its Nu.Q NETs and Capture-PCR programs.

VolitionRx Limited has appointed Dr. Andrew Retter as its Chief Medical Officer, effective April 1, 2024, to provide medical leadership and align scientific efforts with patient needs.